{"issuance_frequency":"","notes_translated":{"fr":"Le virus de l’immunodéficience humaine (VIH) et le virus T‑lymphotrope humain de type 1 (HTLV‑1) sont des exemples d’agents pathogènes du GR3 dont le GR et le NC ont été réévalués par l’Agence, en collaboration avec des spécialistes du VIH et du HTLV et en fonction des risques actuels associés aux activités faisant intervenir ces agents pathogènes. Il a été déterminé qu’il est possible de manipuler le VIH et le HTLV‑1 en toute sécurité à un NC2/NC2‑Ag, à condition de se conformer à certaines exigences opérationnelles supplémentaires (voir la section 4.0). La présente directive en matière de biosécurité vise à donner une vue d’ensemble des résultats des évaluations des risques, des décisions relatives au niveau de confinement qui s’en sont suivies et des aspects qui ont été pris en considération pour les personnes qui travaillent avec ces virus. La Directive en matière de biosécurité portant sur le VIH et le HTLV‑1 doit être consultée en parallèle avec les NLDCB.\r\n","en":"The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG.\r\n"},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"unknown","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"696351a0-3d3b-4d76-a046-b01a16eb1d7d","metadata_created":"2019-02-11T20:51:54.396930","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2019-02-11T20:51:54.396937","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2019-02-11","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["directive","matière","biosécurité","virus de l’immunodéficience humaine","vih","virus","t-lymphotrope","humain","type 1","htlv-1","agents pathogènes","groupes de risque","virus de l’immunodéficience humaine","vih","facteurs de risque","virus t-lymphotrope humain","type 1","htlv-1","facteurs","risque","biosécurité","exigence","opérationnelle","supplémentaire","in vitro","culture","exigence","opérationnelle","supplémentaire","exigence opérationnelle","supplémentaire"],"en":["pathogen","risk groups","human immunodeficiency virus","hiv","description","risk factors","human t-cell","lymphotropic virus","type 1","htlv-1","containment","level","requirements","cbsg","containment zone","containment level","cl","determination","operational requirements","activities","in vivo","biosafety","directive","human","immunodeficiency","virus","hiv","t-cell","type 1","htlv-1"]},"relationships_as_object":[],"creator_user_id":"4cfa9a9c-1d95-40eb-86f9-bc0c8ec45d1f","title_translated":{"fr":"Directive en matière de biosécurité portant sur le virus de l’immunodéficience humaine (VIH) et le virus T-lymphotrope humain de type 1 (HTLV-1)","en":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"696351a0-3d3b-4d76-a046-b01a16eb1d7d","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"54708c77-87c7-4b6c-961f-6ca197266f54","related_relationship":"","name_translated":{"fr":"Directive en matière de biosécurité portant sur le virus de l’immunodéficience humaine (VIH) et le virus T-lymphotrope humain de type 1 (HTLV-1)","en":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)","language":["en"],"created":"2019-02-11T20:51:55.118274","url":"https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/biosafety-directive-human-immunodeficiency-virus-hiv-human-cell-lymphotropic-virus-type-1-htlv-1.html","last_modified":null,"position":0,"revision_id":"e90baeed-1bab-4d43-95ea-4823491c7147","resource_type":"website"},{"cache_last_updated":null,"unique_identifier":"","package_id":"696351a0-3d3b-4d76-a046-b01a16eb1d7d","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"0298b82a-4e1c-4e45-8b38-418fd8d993df","related_relationship":"","name_translated":{"fr":"Directive en matière de biosécurité portant sur le virus de l’immunodéficience humaine (VIH) et le virus T-lymphotrope humain de type 1 (HTLV-1)","en":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)","language":["fr"],"created":"2019-02-11T20:51:55.118283","url":"https://www.canada.ca/fr/sante-publique/services/biosecurite-biosurete-laboratoire/directive-matiere-biosecurite-portant-virus-immunodeficience-humaine-vih-virus-lymphotrope-humain-type-1-htlv-1.html","last_modified":null,"position":1,"revision_id":"e90baeed-1bab-4d43-95ea-4823491c7147","resource_type":"website"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Agence de la santé publique du Canada","en":"Public Health Agency of Canada"},"date_published":"2014-02-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:57.068700","title":"Public Health Agency of Canada | Agence de la santé publique du Canada","name":"phac-aspc","is_organization":true,"state":"active","image_url":"","revision_id":"96161da6-edc7-4d1d-99e0-baac9df7b3b9","type":"organization","id":"1C71053B-AA64-4646-956B-41631C396018","approval_status":"approved"},"name":"696351a0-3d3b-4d76-a046-b01a16eb1d7d","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"The human immunodeficiency virus (HIV) and the human T-cell lymphotropic virus type 1 (HTLV-1) are examples of RG3 pathogens where the pathogen risk and CL assessments have been revisited by the Agency in conjunction with HIV/HTLV specialists based on current risks associated with activities involving these pathogens. It has been determined that HIV & HTLV-1 can be safely handled at CL2/CL2-Ag with specific additional operational requirements (see Section 4.0). This Biosafety Directive is intended to provide a comprehensive overview of the risk assessment outcomes, subsequent CL decisions, and considerations that have been made for those working with HIV and HTLV-1. The Biosafety Directive for HIV and HTLV-1 is to be used in conjunction with the CBSG.\r\n","owner_org":"1C71053B-AA64-4646-956B-41631C396018","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)","revision_id":"e90baeed-1bab-4d43-95ea-4823491c7147"}